Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans

Susanne Lerche, Birgitte Brock, Jørgen Rungby, Hans E. Bøtker, Niels Møller, Anders Rodell, Bo Martin Bibby, Jens J. Holst, Ole Schmitz, Albert Gjedde

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents suggests a protective effect of GLP-1 on brain tissue. The mechanism is unknown. We therefore tested whether these neuroprotective effects could relate to changes of glucose transport and consumption. RESEARCH DESIGN AND METHODS - We studied 10 healthy men in a randomized, double-blinded, placebo-controlled cross-over experiment. We used positron emission tomography to determine the acute insulin-independent effect of GLP-1 on unidirectional glucose transport into the brain during a pituitary- pancreatic normoglycemic (plasma glucose ∼4.5 mmol/l) clamp with 18-fluoro-deoxy-glucose as tracer. RESULTS - On average, GLP-1 reduced cerebral glucose transport by 27% in total cerebral gray matter (P = 0.05) and by 25-30% in individual gray matter regions (P = 0.02-0.06). The same regions revealed a uniform trend toward similarly reduced cerebral glucose metabolism. Consequently, the intracerebral glucose concentration remained constant in all regions, with and without GLP-1. CONCLUSIONS - We have demonstrated that a hormone involved in postprandial glucose regulation also limits glucose delivery to brain tissue and hence provides a possible regulatory mechanism for the link between plasma glucose and brain glucose. Because GLP-1 reduces glucose uptake across the intact blood-brain barrier at normal glycemia, GLP-1 may also protect the brain by limiting intracerebral glucose fluctuation when plasma glucose is increased.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalDiabetes
Volume57
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Glucagon-Like Peptide 1
Blood Glucose
Glucose
Brain
Neuroprotective Agents
Blood-Brain Barrier
Positron-Emission Tomography

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Lerche, S., Brock, B., Rungby, J., Bøtker, H. E., Møller, N., Rodell, A., ... Gjedde, A. (2008). Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes, 57(2), 325-331. https://doi.org/10.2337/db07-1162

Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. / Lerche, Susanne; Brock, Birgitte; Rungby, Jørgen; Bøtker, Hans E.; Møller, Niels; Rodell, Anders; Bibby, Bo Martin; Holst, Jens J.; Schmitz, Ole; Gjedde, Albert.

In: Diabetes, Vol. 57, No. 2, 02.2008, p. 325-331.

Research output: Contribution to journalArticle

Lerche, S, Brock, B, Rungby, J, Bøtker, HE, Møller, N, Rodell, A, Bibby, BM, Holst, JJ, Schmitz, O & Gjedde, A 2008, 'Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans', Diabetes, vol. 57, no. 2, pp. 325-331. https://doi.org/10.2337/db07-1162
Lerche S, Brock B, Rungby J, Bøtker HE, Møller N, Rodell A et al. Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes. 2008 Feb;57(2):325-331. https://doi.org/10.2337/db07-1162
Lerche, Susanne ; Brock, Birgitte ; Rungby, Jørgen ; Bøtker, Hans E. ; Møller, Niels ; Rodell, Anders ; Bibby, Bo Martin ; Holst, Jens J. ; Schmitz, Ole ; Gjedde, Albert. / Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. In: Diabetes. 2008 ; Vol. 57, No. 2. pp. 325-331.
@article{b6fc2486adb84c2184946b220ada6ae4,
title = "Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans",
abstract = "OBJECTIVE - Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents suggests a protective effect of GLP-1 on brain tissue. The mechanism is unknown. We therefore tested whether these neuroprotective effects could relate to changes of glucose transport and consumption. RESEARCH DESIGN AND METHODS - We studied 10 healthy men in a randomized, double-blinded, placebo-controlled cross-over experiment. We used positron emission tomography to determine the acute insulin-independent effect of GLP-1 on unidirectional glucose transport into the brain during a pituitary- pancreatic normoglycemic (plasma glucose ∼4.5 mmol/l) clamp with 18-fluoro-deoxy-glucose as tracer. RESULTS - On average, GLP-1 reduced cerebral glucose transport by 27{\%} in total cerebral gray matter (P = 0.05) and by 25-30{\%} in individual gray matter regions (P = 0.02-0.06). The same regions revealed a uniform trend toward similarly reduced cerebral glucose metabolism. Consequently, the intracerebral glucose concentration remained constant in all regions, with and without GLP-1. CONCLUSIONS - We have demonstrated that a hormone involved in postprandial glucose regulation also limits glucose delivery to brain tissue and hence provides a possible regulatory mechanism for the link between plasma glucose and brain glucose. Because GLP-1 reduces glucose uptake across the intact blood-brain barrier at normal glycemia, GLP-1 may also protect the brain by limiting intracerebral glucose fluctuation when plasma glucose is increased.",
author = "Susanne Lerche and Birgitte Brock and J{\o}rgen Rungby and B{\o}tker, {Hans E.} and Niels M{\o}ller and Anders Rodell and Bibby, {Bo Martin} and Holst, {Jens J.} and Ole Schmitz and Albert Gjedde",
year = "2008",
month = "2",
doi = "10.2337/db07-1162",
language = "English (US)",
volume = "57",
pages = "325--331",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "2",

}

TY - JOUR

T1 - Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans

AU - Lerche, Susanne

AU - Brock, Birgitte

AU - Rungby, Jørgen

AU - Bøtker, Hans E.

AU - Møller, Niels

AU - Rodell, Anders

AU - Bibby, Bo Martin

AU - Holst, Jens J.

AU - Schmitz, Ole

AU - Gjedde, Albert

PY - 2008/2

Y1 - 2008/2

N2 - OBJECTIVE - Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents suggests a protective effect of GLP-1 on brain tissue. The mechanism is unknown. We therefore tested whether these neuroprotective effects could relate to changes of glucose transport and consumption. RESEARCH DESIGN AND METHODS - We studied 10 healthy men in a randomized, double-blinded, placebo-controlled cross-over experiment. We used positron emission tomography to determine the acute insulin-independent effect of GLP-1 on unidirectional glucose transport into the brain during a pituitary- pancreatic normoglycemic (plasma glucose ∼4.5 mmol/l) clamp with 18-fluoro-deoxy-glucose as tracer. RESULTS - On average, GLP-1 reduced cerebral glucose transport by 27% in total cerebral gray matter (P = 0.05) and by 25-30% in individual gray matter regions (P = 0.02-0.06). The same regions revealed a uniform trend toward similarly reduced cerebral glucose metabolism. Consequently, the intracerebral glucose concentration remained constant in all regions, with and without GLP-1. CONCLUSIONS - We have demonstrated that a hormone involved in postprandial glucose regulation also limits glucose delivery to brain tissue and hence provides a possible regulatory mechanism for the link between plasma glucose and brain glucose. Because GLP-1 reduces glucose uptake across the intact blood-brain barrier at normal glycemia, GLP-1 may also protect the brain by limiting intracerebral glucose fluctuation when plasma glucose is increased.

AB - OBJECTIVE - Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents suggests a protective effect of GLP-1 on brain tissue. The mechanism is unknown. We therefore tested whether these neuroprotective effects could relate to changes of glucose transport and consumption. RESEARCH DESIGN AND METHODS - We studied 10 healthy men in a randomized, double-blinded, placebo-controlled cross-over experiment. We used positron emission tomography to determine the acute insulin-independent effect of GLP-1 on unidirectional glucose transport into the brain during a pituitary- pancreatic normoglycemic (plasma glucose ∼4.5 mmol/l) clamp with 18-fluoro-deoxy-glucose as tracer. RESULTS - On average, GLP-1 reduced cerebral glucose transport by 27% in total cerebral gray matter (P = 0.05) and by 25-30% in individual gray matter regions (P = 0.02-0.06). The same regions revealed a uniform trend toward similarly reduced cerebral glucose metabolism. Consequently, the intracerebral glucose concentration remained constant in all regions, with and without GLP-1. CONCLUSIONS - We have demonstrated that a hormone involved in postprandial glucose regulation also limits glucose delivery to brain tissue and hence provides a possible regulatory mechanism for the link between plasma glucose and brain glucose. Because GLP-1 reduces glucose uptake across the intact blood-brain barrier at normal glycemia, GLP-1 may also protect the brain by limiting intracerebral glucose fluctuation when plasma glucose is increased.

UR - http://www.scopus.com/inward/record.url?scp=40749107089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749107089&partnerID=8YFLogxK

U2 - 10.2337/db07-1162

DO - 10.2337/db07-1162

M3 - Article

C2 - 17991759

AN - SCOPUS:40749107089

VL - 57

SP - 325

EP - 331

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 2

ER -